Treatment with a pharmaceutical composition comprising MANF2 necleic acid

• US 8,980,821 B2
• Filed: 04/15/2011
• Issued: 03/17/2015
• Est. Priority Date: 08/30/2002
• Status: Expired due to Term

• Current Assignee: Herantis Pharma PLC
• Original Assignee: Herantis Pharma PLC
• Inventors: Saarma, Mart, Lauren, Juha, Lindholm, Pivi, Timmusk, Tonis, Tuominen, Raimo
• Primary Examiner(s): Marvich, Maria
• Application Number:
  US13/088,233
• Publication Number:
  US 20110251132A1
• Time in Patent Office: 1,432 Days
• Field of Search: None
• US Class Current: 514/1.1
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A01K 2217/075 inducing loss of function, i.e. knock out
• CPC Class Codes: A01K 2227/105 Murine
• CPC Class Codes: A01K 2267/0356 Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 25/30 for treating abuse or dependence
• CPC Class Codes: C07K 14/475 Growth factors; Growth regulators

Abstract

A method for treating a condition in a patient, wherein the condition is selected from the group consisting of Alzheimer'"'"'s disease, Parkinson'"'"'s disease, amyotrophic lateral sclerosis, stroke and peripheral neuropathy. The method consists of administering to the patient a pharmaceutically effective amount of a pharmaceutical composition comprising the MANF2 polypeptide of SEQ ID NO:2 or a functional fragment thereof.

Claims

1. A method of treating the symptoms of Parkinson'"'"'s disease in a patient in need thereof, the method comprising:

directly administering to the central nervous system of the patient a pharmaceutically effective amount of a pharmaceutical composition comprising the MANF2 polypeptide of SEQ ID NO;

2 or a functional fragment thereof, wherein said functional fragment is capable of preventing the 6-hydroxydopamine (6-OHDA)-induced degeneration of dopaminergic neurons, and wherein said functional fragment comprises amino acids 27-187 of the amino acid sequence of SEQ ID NO;

2.

2. The method of claim 1 wherein the pharmaceutical composition comprises SEQ. ID NO:

2.

3. The method of claim 1, wherein the functional fragment consists of amino acids 27-187 of the amino acid sequence of SEQ ID NO:

2.